Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

ING3 promotes prostate cancer growth by activating the androgen receptor.

Nabbi A, McClurg UL, Thalappilly S, Almami A, Mobahat M, Bismar TA, Binda O, Riabowol KT.

BMC Med. 2017 May 16;15(1):103. doi: 10.1186/s12916-017-0854-0.

2.

Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.

Cucchiara V, Yang JC, Mirone V, Gao AC, Rosenfeld MG, Evans CP.

Cancers (Basel). 2017 Jan 16;9(1). pii: E9. doi: 10.3390/cancers9010009. Review.

3.

Acetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis.

DePaolo JS, Wang Z, Guo J, Zhang G, Qian C, Zhang H, Zabaleta J, Liu W.

Oncotarget. 2016 Nov 1;7(44):71417-71428. doi: 10.18632/oncotarget.12163.

4.

Divergent Binding and Transactivation by Two Related Steroid Receptors at the Same Response Element.

Tesikova M, Dezitter X, Nenseth HZ, Klokk TI, Mueller F, Hager GL, Saatcioglu F.

J Biol Chem. 2016 May 27;291(22):11899-910. doi: 10.1074/jbc.M115.684480. Epub 2016 Apr 7.

5.

Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.

Wadosky KM, Koochekpour S.

Int J Biol Sci. 2016 Feb 6;12(4):409-26. doi: 10.7150/ijbs.14090. eCollection 2016. Review.

6.

CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.

Sun H, Mediwala SN, Szafran AT, Mancini MA, Marcelli M.

Horm Cancer. 2016 Jun;7(3):196-210. doi: 10.1007/s12672-016-0257-2. Epub 2016 Mar 8.

7.

Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Foley C, Mitsiades N.

Horm Cancer. 2016 Apr;7(2):84-103. doi: 10.1007/s12672-015-0239-9. Epub 2016 Jan 4. Review.

8.

HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.

Ruscetti M, Dadashian EL, Guo W, Quach B, Mulholland DJ, Park JW, Tran LM, Kobayashi N, Bianchi-Frias D, Xing Y, Nelson PS, Wu H.

Oncogene. 2016 Jul 21;35(29):3781-95. doi: 10.1038/onc.2015.444. Epub 2015 Dec 7.

9.
10.

Dichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer Cells.

Pathak R, Philizaire M, Mujtaba S.

Cancers (Basel). 2015 Aug 19;7(3):1622-42. doi: 10.3390/cancers7030854. Review.

11.

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.

O'Neill D, Jones D, Wade M, Grey J, Nakjang S, Guo W, Cork D, Davies BR, Wedge SR, Robson CN, Gaughan L.

Oncotarget. 2015 Sep 22;6(28):26029-40. doi: 10.18632/oncotarget.4347.

12.

Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.

Di Sante G, Pestell TG, Casimiro MC, Bisetto S, Powell MJ, Lisanti MP, Cordon-Cardo C, Castillo-Martin M, Bonal DM, Debattisti V, Chen K, Wang L, He X, McBurney MW, Pestell RG.

Am J Pathol. 2015 Jan;185(1):266-79. doi: 10.1016/j.ajpath.2014.09.014.

13.

Distinctly different dynamics and kinetics of two steroid receptors at the same response elements in living cells.

Nenseth HZ, Dezitter X, Tesikova M, Mueller F, Klokk TI, Hager GL, Saatcioglu F.

PLoS One. 2014 Aug 18;9(8):e105204. doi: 10.1371/journal.pone.0105204. eCollection 2014.

14.

Coactivator MYST1 regulates nuclear factor-κB and androgen receptor functions during proliferation of prostate cancer cells.

Jaganathan A, Chaurasia P, Xiao GQ, Philizaire M, Lv X, Yao S, Burnstein KL, Liu DP, Levine AC, Mujtaba S.

Mol Endocrinol. 2014 Jun;28(6):872-85. doi: 10.1210/me.2014-1055. Epub 2014 Apr 4.

15.

Minireview: The versatile roles of lysine deacetylases in steroid receptor signaling.

Kadiyala V, Smith CL.

Mol Endocrinol. 2014 May;28(5):607-21. doi: 10.1210/me.2014-1002. Epub 2014 Mar 19. Review.

16.

p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis.

Zhong J, Ding L, Bohrer LR, Pan Y, Liu P, Zhang J, Sebo TJ, Karnes RJ, Tindall DJ, van Deursen J, Huang H.

Cancer Res. 2014 Mar 15;74(6):1870-1880. doi: 10.1158/0008-5472.CAN-13-2485. Epub 2014 Jan 30.

17.

Long and noncoding RNAs (lnc-RNAs) determine androgen receptor dependent gene expression in prostate cancer growth in vivo.

Pestell RG, Yu Z.

Asian J Androl. 2014 Mar-Apr;16(2):268-9. doi: 10.4103/1008-682X.122364.

18.

Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation.

Wu K, Chen K, Wang C, Jiao X, Wang L, Zhou J, Wang J, Li Z, Addya S, Sorensen PH, Lisanti MP, Quong A, Ertel A, Pestell RG.

Cancer Res. 2014 Feb 1;74(3):829-39. doi: 10.1158/0008-5472.CAN-13-2466. Epub 2013 Dec 12.

19.

Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Chua JP, Lieberman AP.

CNS Neurol Disord Drug Targets. 2013 Dec;12(8):1146-56. Review.

20.

lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs.

Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP, Rosenfeld MG.

Nature. 2013 Aug 29;500(7464):598-602. doi: 10.1038/nature12451. Epub 2013 Aug 14.

Supplemental Content

Support Center